Novo Nordisk books DKK 6.3 billion in non-cash pipeline impairments, including monlunabant

Novo Nordisk reported a 16% drop in reported second-quarter operating profit at constant exchange rates, driven by DKK 6.3 billion in non-cash impairment charges on intangible pipeline assets ^[1][2]. About DKK 4.0 billion of that charge relates to monlunabant, an oral obesity drug candidate the company has discontinued ^[1][2].

On an adjusted basis, which strips out the impairments and a one-time effect from the US 340B rebate program, the picture looks different. Adjusted sales for the quarter rose 7% at constant exchange rates to DKK 78,488 million, and adjusted operating profit climbed 11% to DKK 33,389 million ^[1]. The company said this adjusted growth was driven by strong GLP-1 volume ^[2].

The reported decline in profit also reflects a tough comparison from last year. In the same quarter of 2025, Novo Nordisk had reversed a DKK 2.6 billion provision tied to the US 340B Drug Pricing Program, a one-time gain that inflated the prior year's reported results and made this year's numbers look worse by comparison ^[1][2].

Despite the write-downs, Novo Nordisk raised its full-year 2026 outlook. The company now expects adjusted sales growth of 0% to -6% at constant exchange rates, up from a previous range of -4% to -12%. Adjusted operating profit growth guidance was similarly raised to 0% to -6% from -4% to -12% ^[1][2]. Novo Nordisk said the improved outlook reflects higher expectations for GLP-1 product sales ^[1]. On a non-adjusted basis, the midpoints of the new guidance imply 5% sales growth and 12% operating profit growth for the year ^[1].

The company also returned DKK 41.2 billion to shareholders through dividends and share buybacks in the first half of 2026 ^[2]. On the commercial side, Wegovy's oral pill topped 5 million prescriptions in the US since launch and kept its lead among branded obesity drugs, while the company also rolled out a higher-dose Wegovy pen and expanded into new markets including the UAE and UK ^[2]. Not every pipeline result was positive: a large trial of the cardiovascular drug candidate ziltivekimab failed to meet its main goal, even as regulators in Europe cleared Wegovy pill and high-dose formulations ^[2].

Why it matters for patients

For people currently taking Wegovy, Ozempic, or Rybelsus, this earnings report does not change access, price, or dosing. It is a financial disclosure about how Novo Nordisk accounts for a canceled drug in its pipeline, not a safety or supply issue affecting products on the market ^[1][2].

The end of monlunabant does mean one fewer oral obesity drug candidate is moving toward approval, which could affect how many pill-based options eventually reach pharmacies over the next several years. Patients weighing oral versus injectable GLP-1 treatments should know that the company's near-term pipeline for new oral obesity drugs has narrowed with this discontinuation ^[1].

The raised sales outlook, tied to strong demand for GLP-1 medicines including the Wegovy pill, suggests the company expects continued growth in prescriptions and possibly continued investment in manufacturing capacity, though the sources do not detail specific supply commitments for the US market ^[1][2].

What happens next

Novo Nordisk held an investor conference call on 5 August 2026 to discuss the results in more detail ^[1]. The sources do not specify further milestones for monlunabant or say whether any other pipeline obesity candidates face similar review. It is not yet known from these sources what, if anything, replaces monlunabant in the company's oral obesity pipeline.